← Leaderboards
Frank J. Accurso
University Of Colorado Denver
$3,381,974
Attributed
$3,381,974
Total exposure
30
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–08$2M$1.5M$1M$500K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$7,443,877 · 31
By mechanism
U01$4,180,727 · 2
R01$2,287,423 · 1
M01$975,727 · 28
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Ronald J Sokol$193,385,254
- Jeffrey S Wagener$153,271
- Mary Elaine Reyland$13,618,689
- Trevor Joseph Isner$75,882
- Marci K Sontag$1,351,396
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisHuman SubjectClinical ResearchPathologic ProcessPatient Oriented ResearchHuman Therapy EvaluationComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelGrantDrug Screening /EvaluationLung DisorderInstitutionSourceFundingUnited States National Institutes Of HealthResourcesEnzyme ActivityNewborn Human (0-6 Weeks)Early DiagnosisGenotypeInhalation Drug AdministrationCystic Fibrosis PatientsBiomarkerInflammation
Grant awards (43)
Clinical Proteomics Center in Lung Disease$981,007
U01 · FY2008 · HL · contact PI
Clinical Proteomics Center in Lung Disease$1,001,028
U01 · FY2007 · HL · contact PI
BIOMARKERS OF DISEASE PROGRESSION IN CHILDREN W/CF IDENTIFIED BY NEWBORN SCREEN$108,883
M01 · FY2007 · RR · contact PI
PTC124 AS AN ORAL TREATMENT FOR NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS$30,267
M01 · FY2007 · RR · contact PI
OPEN-LABEL AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS$26,208
M01 · FY2007 · RR · contact PI
THE EPIC OBSERVATIONAL STUDY$22,146
M01 · FY2007 · RR · contact PI
PHARMACOKINETICS OF ORAL LIPOIC ACID IN CYSTIC FIBROSIS PATIENTS$14,397
M01 · FY2007 · RR · contact PI
PHARMACOKINETICS OF 552-02 FOLLOWING 14 DAYS OF DOSING BY INHALATION IN PTS W/CF$6,277
M01 · FY2007 · RR · contact PI
TREATMENT OF NEW ONSET PSEUDOMONAS AERUGINOSA IN YOUNG PTS WITH CYSTIC FIBROSIS$4,431
M01 · FY2007 · RR · contact PI
AZTREONAM LYSINATE FOR INHALATION FOR CYSTIC FIBROSIS$3,692
M01 · FY2007 · RR · contact PI
Clinical Proteomics Center in Lung Disease$1,030,926
U01 · FY2006 · HL · contact PI
BIOMARKERS OF DISEASE PROGRESSION IN CHILDREN W/CF IDENTIFIED BY NEWBORN SCREEN$166,885
M01 · FY2006 · RR · contact PI
THE EPIC OBSERVATIONAL STUDY$29,164
M01 · FY2006 · RR · contact PI
AZTREONAM LYSINATE FOR INHALATION FOR CYSTIC FIBROSIS$22,144
M01 · FY2006 · RR · contact PI
OPEN-LABEL AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS$14,043
M01 · FY2006 · RR · contact PI
PTC124 AS AN ORAL TREATMENT FOR NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS$11,881
M01 · FY2006 · RR · contact PI
TREATMENT OF NEW ONSET PSEUDOMONAS AERUGINOSA IN YOUNG PTS WITH CYSTIC FIBROSIS$3,240
M01 · FY2006 · RR · contact PI
PHARMACOKINETICS OF 552-02 FOLLOWING 14 DAYS OF DOSING BY INHALATION IN PTS W/CF$1,620
M01 · FY2006 · RR · contact PI
Clinical Proteomics Center in Lung Disease$1,048,942
U01 · FY2005 · HL
BIOMARKERS OF DISEASE PROGRESSION IN CHILDREN W/CF IDENTIFIED BY NEWBORN SCREEN$179,797
M01 · FY2005 · RR
ADMINISTRATIVE CORE$118,824
U01 · FY2005 · HL
MULTICENTER, PHASE II STUDY OF AEROSOLIZED TGAAVCF FOR THE TREATMENT OF CF$46,914
M01 · FY2005 · RR
ASSESSING THE VARIABILITY OF IMMUNOREACTIVE TRYPSINOGEN IN CHILDREN WITH CF$20,994
M01 · FY2005 · RR
A PHASE IIA, SAFETY AND EFFICACY STUDY OF ORAL SPI-8811 IN PATIENTS WITH CF$6,460
M01 · FY2005 · RR
Determinants of early pancreatic injury in cystic fibro*$565,559
R01 · FY2004 · DK
Biomarkers of Disease Progression in Children w/CF Identified by Newborn Screen$120,385
M01 · FY2004 · RR
Sleep Efficiency in Young CF Pts. During Hospitalization$7,827
M01 · FY2004 · RR
A Phase IIa, Safety and Efficacy Study of Oral SPI-8811 in Patients with CF$4,472
M01 · FY2004 · RR
PhaseII Study of Aerosolized tgAAVCF for Treatment of CF$3,354
M01 · FY2004 · RR
Nasal Potential Difference Measurements in Patients with CF &Normal Individuals$1,086
M01 · FY2004 · RR
Determinants of early pancreatic injury in cystic fibro*$566,376
R01 · FY2003 · DK
Determinants of early pancreatic injury in cystic fibro*$576,584
R01 · FY2002 · DK
CYSTIC FIBROSIS NEWBORN SCREENING--LONGITUDINAL FOLLOWUP$0
M01 · FY2002 · RR
INS365 IN ADULT &PEDIATRIC CYSTIC FIBROSIS PATIENTS$0
M01 · FY2002 · RR
EFFECT OF AEROSOLIZED HYPERTONIC SALINE IN CYSTIC FIBROSIS$0
M01 · FY2002 · RR
Determinants of pancreatic injury in cystic fibrosis$578,904
R01 · FY2001 · DK
SAFETY AND EFFICACY OF INHALED CORTICOSTEROIDS IN CHILDREN WITH CYSTIC FIBROSIS$19,860
M01 · FY2000 · RR
INS365 IN ADULT &PEDIATRIC CYSTIC FIBROSIS PATIENTS$19,860
M01 · FY2000 · RR
MEROPENEM FOR TREATMENT OF ACUTE PULMONARY EXACERBATIONS IN PATIENTS W/ CF$19,860
M01 · FY2000 · RR
EFFECT OF AEROSOLIZED HYPERTONIC SALINE IN CYSTIC FIBROSIS$19,860
M01 · FY2000 · RR
EVALUATE LUNG SPECIFIC BIOEFFICACY OF DMP777 IN PTS 18YRS &OLDER W/ CF$19,860
M01 · FY2000 · RR
STUDY TO COMPARE THE SAFETY AND EFFICACY OF ULTRASE MT12 TO PLACEBO IN CF$19,860
M01 · FY2000 · RR
CYSTIC FIBROSIS NEWBORN SCREENING--LONGITUDINAL FOLLOWUP$0
M01 · FY2000 · RR